Home » Newsletters » BioWorld Science

BioWorld Science

April 28, 2003

View Archived Issues

Cel-Sci receives SBIR grant to develop treatment for autoimmune myocarditis

Methods of inhibiting cancer metastasis using polypeptides targeting chemokine receptors

Novel IKK-2 inhibitors prepared and tested at Pharmacia

Pyrazole-based antiproliferative agents covered by Bayer patent

Beta3-adrenoceptor agonists and their use in obesity, diabetes, etc.

Antibacterial agents with RNase-based mechanism of action discovered at Message

Mitsubishi Pharma and Sanofi-Synthelabo present new TPK1 inhibitors for AD

Novel vitamin D3 analogues with utility in osteoporosis and other disorders under study at Roche

Novo Nordisk presents new DPP-IV inhibitors

Axcan responds to Salix's rejection of cash tender offer

Serono initiates phase I trial of beta-sheet breaker peptide for Alzheimer's disease

AVI-4020 completes preclinical testing

TTS-CD2 prolongs survival in NSCLC

Tostrex rebranded Fortigel

Cypher stent approved by FDA

FavId phase II study expanded

Genesis Research and EvoGenix collaborate on antiinflammatory discovery

DCVax-Direct Adjuvant Cancer Therapy shows positive results in mice

FDA lifts clinical hold on Skeletal Targeted Radiotherapy

IND filed for phase III bromfenac studies

Positive Visicol laxative study results announced

Phase III findings for Extina in seborrheic dermatitis to support NDA filing

INGN-241 effective in ovarian cancer in preclinical study

LymphoStat-B is biologically active in patients with SLE

Drotrecogin alfa (activated) reduces mortality and organ failure in severe sepsis

The effects of sPLA2 inhibitor on the survival rate of patients with severe sepsis

Merck discontinues development of lead PDE4 inhibitor

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.